SUTRO BIOPHARMA, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M | -$98.5M |
| Operating expenses | $260.9M | $300.5M | $243.0M | $196.7M | $160.4M |
| Cash from operations | -$177.2M | -$191.5M | -$111.6M | $3.5M | -$81.7M |
| Capital expenditure | $11,000 | $673,000 | $214,000 | $280,000 | $370,000 |
| Free cash flow | -$177.2M | -$192.2M | -$111.8M | $3.3M | -$82.0M |
| Share repurchases | — | — | — | — | $7,000 |
| Impairments | $1.7M | $0 | — | — | — |
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M |
| Total debt | — | — | $3.1M | $15.6M | $25.0M |
Shares outstanding 16.6M · Free float 60.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.